ONCOLOGY SMALL MOLECULE DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-151721 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Oncology Small Molecule Drugs Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET

7.1 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA ONCOLOGY SMALL MOLECULE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Pfizer Inc

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 F. Hoffman

16.3 Sanofi S.A

16.4 AbbVie Inc

16.5 Incyte Corporation

16.6 AstraZeneca plc

16.7 Millennium Pharmaceuticals

16.8 Novartis AG

16.9 Amgen Inc

16.10 Eli Lilly and Company

16.11 Bristol-Myers Squibb Company

16.12 Bayer AG

16.13 Celgene Corporation

16.14 Exelixis Inc

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Drug Class
Chemotherapy Drugs
  o Alkylating Agents
  o Antimetabolites
  o Other Drugs
Immunomodulating Drugs
Hormonal Therapy
Targeted Therapy Drugs
  o Proteasome Inhibitors
  o Tyrosine Kinase Inhibitors
  o mTOR Inhibitors
  o Others

By Indication Type
Breast Cancer
Prostate Cancer
Multiple Myeloma
Melanoma
Lymphoma
Leukemia
Non-small Cell Lung Cancer (NSCLC)
Renal Cell Carcinoma
Others

By Route of Administration
Oral
Injectable

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Specialty Clinics
Online Pharmacies

Companies

Pfizer Inc
F. Hoffman
Sanofi S.A
AbbVie Inc
Incyte Corporation
AstraZeneca plc
Millennium Pharmaceuticals
Novartis AG
Amgen Inc
Eli Lilly and Company
Bristol-Myers Squibb Company
Bayer AG
Celgene Corporation
Exelixis Inc

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.